Raising the bar on RWE: addressing the challenges of research and industry with AI and NLP
Available to watch now on demand
- Are you in Pharma and keen to improve your RWE project or RWD for regulatory approval?
- Are you a researcher yearning for exciting RWE projects to transform patient outcomes?
The future of real-world evidence generation has arrived. Experts from Savana, Janssen and BREATHE will discuss their experiences of the value of utilizing clinical natural language processing (cNLP) on electronic health records. Discover why evidence generation techniques need to evolve to break through the challenges of traditional methods and how cNLP can help generate ‘deep real-world evidence (RWE)’. Plus, hear how advanced AI techniques in pharma can assist researchers, clinicians and industry alike.
What will you learn?
- RWE from the perspectives of the principal investigator and the pharma executive
- The limitations of traditional methods of evidence generation from electronic health records
- The benefits of AI-based techniques such as cNLP
- A gold standard for high-quality RWE for deeper insights at scale and speed
Who may this interest?
- Hospital CIs
- Pharma/Biotech RWE
- Medical Affairs
Chief Scientific Officer
Miren graduated from the Navarra University Medical School (Spain) in 2008, finishing her medical oncology training at the Catalan Institute of Oncology (ICO) in Barcelona (Spain) in 2013. Internationally, she joined the head and neck cancer unit at the Dana Farber Cancer Institute as a fellowship, in Boston, USA. Additionally, she developed part of her Ph.D at Saint James Cancer Center in Ohio University, USA. In 2019, Miren defended her Ph.D. about the impact of Human Papillomavirus (HPV) in oropharyngeal cancer, receiving two relevant awards from the University of Barcelona (Spain), best Ph.D. in Medicine (Extraordinary Award), and the certificate of recognition within all university degrees of the year.
Miren is author of 38 scientific articles published in high-impact international journals (ORCID). Furthermore, she has also participated in several scientific congresses and events, such as the American Society of Oncology (ASCO, VA, USA) as a chairwoman of the head and neck poster discussion session. In addition, she has taken part in numerous international clinical trials, university teaching activities, writing several guidelines, and book chapters within the oncological field. In 2020 she started working in Savana to develop the scientific department, conveying her clinical and research knowledge to find the applicability of AI models to advance science and impacting patients’ outcome.
Professor Jennifer Quint
Deputy Director and Programme Lead – RWE at BREATHE – The Health Data Research Hub for Respiratory Health
Professor of Respiratory Epidemiology at the National Heart and Lung Institute and Honorary Consultant Physician in Respiratory Medicine at the Royal Brompton and Imperial College London NHS Foundation Trusts (UK)
Jennifer Quint received her BSc MBBS degrees from the University of London before going on to gain a PhD from University College London and an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, UoL (all UK). She is currently a Professor of Respiratory Epidemiology at the National Heart and Lung Institute (NHLI), Imperial College London, and an Honorary Consultant. She leads a clinical epidemiology research group whose work centres largely on understanding the relationship between cardiovascular and respiratory disease as well as maximising the quality, linkage and usage of routinely collected data for clinical and research purposes. She partners with the Royal College of Physicians and is Analysis Lead for the National Asthma and COPD Audit Programme. She currently serves as an associate editor for Thorax and is the Information Governance Trustee for the British Thoracic Society.
EMEA Medical Advisor, Oncology, Janssen. Europe, Middle East & Africa (EMEA)
Angela received her pharmacy degree from the Complutense University of Madrid (Spain) before gaining a masters degree in clinical trials monitoring. Specializing in oncology, she has over 15 years experience in clinical trials and scientific liaison management in Spain. Currently, she is Janssen’s Oncology Medical Advisor for Europe, Middle East & Africa (EMEA) and is currently managing innovative electronic health record (EHR)-based RWE studies in the field of prostate cancer in EMEA. Encompassing both descriptive and predictive studies, the results will contribute to improving prostate cancer disease management and patients’ quality of life worldwide.
In association with